EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial

Ilaria Colombo, Pascale C S Rietveld, Stefanie Fischer, Stefania Merlo, Ursula Vogl, Richard Cathomas, Stijn L W Koolen, Daniela Zoelly, Katrin Gobat, Charlotte Micheloud, Katrin Eckhardt, Cristiana Sessa und 3 weitere

Cancer Chemotherapy and Pharmacology · 2026

DOI: 10.1007/s00280-026-04933-6 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Ilaria Colombo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Docetaxel, Antineoplastic Agents. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Vivesto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Docetaxel micellar (DM) is a novel polysorbate-free docetaxel formulation that does not require steroid premedication. The aim of this study was to define the safety, pharmacokinetics (PK) and preliminary activity of DM in patients with metastatic castration-resistant prostate cancer (mCRPC).

Methods

DM was administered intravenously to chemotherapy-naïve patients with mCRPC every 3 weeks following a 3 + 3 design (75, 90, 100 mg/m^2) until disease progression or unacceptable toxicity (maximum 10 cycles).

Results

A total of 11 patients were recruited from June 2021 to April 2023. No dose limiting toxicities (DLT) were observed at 75 or 90 mg/m^2. Two out of 5 patients experienced DLT at 100 mg/m^2 (grade 4 neutropenia ≥ 7 days and grade 2 nausea/fatigue/diarrhoea requiring dose reduction at cycle 2, respectively). Most frequent all-grades TRAE included fatigue (91%), neutropenia (82%), alopecia (64%), diarrhoea (55%), peripheral edema (45%) and peripheral sensory neuropathy (45%). Infusion-related reactions or febrile neutropenia were not observed. Four out of 11 (36%) patients achieved a PSA50 response, 4/9 (44%) evaluable patients achieved a radiological response. DM exhibited linear PK with tri-phasic elimination (clearance 26.6 L/h, 20% inter-individual PK variability). While 3-weekly intravenous DM at 90 mg/m^2 was not associated with DLT, no formal dosing recommendation was made for premature closure of the 100 mg/m^2 cohort.

Conclusions

Steroid-free 3-weekly DM at a dose of 90 mg/m2 was not associated with DLT. Preliminary activity of DM appeared consistent with historical outcomes reported for conventional docetaxel in patients with mCRPC (NCT04629781).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantDocetaxelAntineoplastic AgentsHumansMaleAgedMicellesMiddle AgedDose-Response Relationship, DrugMaximum Tolerated Dose

Stichwörter der Autor:innen

Docetaxel micellarMetastatic castration-resistant prostate cancerPhase 1 dose-escalationProstate cancerSteroid-free chemotherapy

Substanzen

DocetaxelMicellesAntineoplastic Agents

Autor:innen und Institutionen

  • Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
  • Department of Medical Oncology and Hospital Pharmacy, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Medical Oncology and Hematology, Kantonsspital, Health Ostschweiz (HOCH), Rorschacherstrasse 95, St. Gallen, CH-9007, Switzerland.
  • Division of Oncology and Hematology, Kantonsspital Graubünden, Chur, Switzerland.
  • Competence Center of Swiss Cancer Institute (SCI), Bern, Switzerland.

Förderung

  • Vivesto

Zitieren

APA

Colombo, I., Rietveld, P. C. S., Fischer, S., Merlo, S., Vogl, U., Cathomas, R., Koolen, S. L. W., Zoelly, D., Gobat, K., Micheloud, C., Eckhardt, K., Sessa, C., Stathis, A., Omlin, A., & Joerger, M. (2026). Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04933-6

Vancouver

Colombo I, Rietveld PCS, Fischer S, Merlo S, Vogl U, Cathomas R, et al. Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-026-04933-6

BibTeX
@article{Colombo2026,
  author = {Colombo, Ilaria and Rietveld, Pascale C S and Fischer, Stefanie and Merlo, Stefania and Vogl, Ursula and Cathomas, Richard and Koolen, Stijn L W and Zoelly, Daniela and Gobat, Katrin and Micheloud, Charlotte and Eckhardt, Katrin and Sessa, Cristiana and Stathis, Anastasios and Omlin, Aurelius and Joerger, Markus},
  title = {Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  doi = {10.1007/s00280-026-04933-6}
}
Kostenlos starten →